Arbeitsgruppe Ösophagus-/Magen-Karzinome - Studien
| Stadium II/III Adenokarzinom des Magens oder gastroösophagealen Übergangs – neoadjuvante/ perioperative Therapie |
| AIO-Studie | |
zur Studie | ||
| AIO-STO-0215: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of AIO/CAO-V/CAOGI (RENAISSANCE / FLOT5) Weitere Informationen zur Studie finden Sie hier! Pressemitteilung zur RENAISSANCE-Studie mehr |
||||
| ---in Rekrutierung; weitere Zentren nur auf Anfrage --- | ||||
| AIO-Studie | www.clinicaltrials.gov |
zur Studie | ||
| AIO-STO-0317: A randomized, open-label Phase II efficacy and safety study of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction (MO30039) - DANTE-Trial | ||||
| ---in Rekrutierung--- | ||||
| AIO-assoziierte Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-STO-0319/ass: Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Typ II/III adenocarcinoma - A phase III trial of the AIO/CAOGI/ACO (FLOT-9) |
||||
| ---in Vorbereitung--- | ||||
| Locally advanced, resectable adenocarcinoma of the esophagogastric junction |
| AIO-Studie | Für weitere Zentren offen |
zur Studie | ||
| AIO-STO-0118: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) - A randomized phase III joint study of the AIO, ARO and DGAV (RACE-trial) | ||||
| ---in Vorbereitung--- | ||||
| Lokal fortgeschrittenes oder metastasiertes Adenokarzinom des Magens oder gastroösophagealen Übergangs - palliative Therapie, 1st-line |
| AIO-Studie | Für weitere Zentren offen |
www.clinicaltrials.gov | zur Studie | |
| AIO-STO-0217: Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma The randomized phase 2 INTEGA trial. |
||||
| ---in Rekrutierung--- |
||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-STO-0417: Modified FOLFOX plus/minus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - The randomized phase 2 MOONLIGHT trial. (A study of the AIO) | ||||
| ---geschlossen, erneute Öffnung der Studie nach Amendment geplant--- | ||||
| Lokal
fortgeschrittenes oder metastasiertes Adenokarzinom des Magens oder
gastroösophagealen Übergangs - palliative Therapie, 2nd-line |
| AIO-Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-STO-0415: A randomized, open label phase II trial of Irinotecan / Folinic Acid / 5-FU plus Ramucirumab versus Paclitaxel plus Ramucirumab in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy (RAMIRIS) | ||||
| ---in Rekrutierung--- | ||||
| AIO-assoziierte Studie | Für weitere Zentren offen | |
zur Studie | |
| AIO-STO-0419/ass: A study of Ramucirumab beyond progression plus TAS- 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy - RE- ExPEL | ||||
| ---in Vorbereitung --- | ||||
| Metastasiertes/fortgeschrittenes Magenkarzinom, Second-Line (2nd Line) |
| AIO-Studie | Für weitere Zentren offen |
www.clinicaltrialsregister.eu | zur Studie | |
| AIO-STO-0218: Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO (The RAP Trial) |
||||
| ---in Rekrutierung--- | ||||
| Plattenepithelkarzinom des Ösophagus, Zweitlinientherapie |
| AIO-assoziierte Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-STO-0216/ass: A randomized, multicenter open label phase II trial of Paclitaxel + Ramucirumab versus Paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based drugs – The RAMOS study | ||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-STO-0117: A multicenteR open-label phase II triAl to evaluate NivoluMab and Ipilimumab fOr 2nd line therapy in elderly patieNts with advanced esophageal squamous cell cAncer [RAMONA] | ||||
| ---in Rekrutierung--- | ||||
| Register: Hepatozelluläres Karzinom / Gallengangskarzinom / Gallenblasenkarzinom / Pankreaskarzinom / Magen- und Speiseröhrenkarzinom – palliativ, first line |
| AIO-assoziierte Studie | zum Platon-Netzwerk | zur Studie | ||
| AIO-HEP/STO-0219/ass: Platform for Analyzing Targetable Tumor Mutations - PLATON |
||||
| ---in Vorbereitung --- | ||||
| LETZTE AKTUALISIERUNG DIESER SEITE AM: 01.05.2020 |